Table 2.
Frequency and standardized incidence ratio of SPM by radiation.
| None/unknown | Radioisotopes | Beam radiation | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Observed | O/E | 95% CI | Observed | O/E | 95% CI | Observed | O/E | 95% CI | |
| All sites | 1,511 | 1.09# | 1.03–1.14 | 1,124 | 1.16# | 1.1–1.23 | 82 | 1.15 | 0.92–1.43 |
| All solid tumors | 1,356 | 1.09# | 1.03–1.15 | 981 | 1.13# | 1.06–1.2 | 75 | 1.19 | 0.93–1.49 |
| Oral cavity and pharynx | 21 | 0.77 | 0.48–1.18 | 34 | 1.70# | 1.18–2.38 | 3 | 2.33 | 0.48–6.81 |
| Salivary gland | 6 | 1.78 | 0.65–3.87 | 19 | 7.88# | 4.74–12.3 | 2 | 12.44# | 1.51–44.95 |
| Colon, rectum and anus | 115 | 0.83# | 0.69–1 | 85 | 0.94 | 0.75–1.16 | 15 | 1.88# | 1.05–3.11 |
| Colon excluding rectum | 89 | 0.92 | 0.74–1.13 | 62 | 1.02 | 0.78–1.31 | 12 | 2.08# | 1.07–3.63 |
| Rectum | 15 | 0.56# | 0.32–0.93 | 13 | 0.69 | 0.37–1.18 | 2 | 1.46 | 0.18–5.27 |
| Bones and joints | 5 | 3.10# | 1.01–7.24 | 5 | 3.94# | 1.28–9.2 | 0 | 0 | 0–50.45 |
| Skin | 80 | 1.24 | 0.99–1.55 | 68 | 1.42# | 1.1–1.8 | 4 | 1.48 | 0.4–3.8 |
| Melanoma | 72 | 1.22 | 0.96–1.54 | 59 | 1.34# | 1.02–1.72 | 4 | 1.65 | 0.45–4.22 |
| Breast | 356 | 1.12# | 1.01–1.24 | 245 | 1.08 | 0.95–4.7 | 24 | 1.4 | 0.9–2.08 |
| Prostate | 152 | 1.22# | 1.03–1.43 | 126 | 1.40# | 1.17–1.68 | 8 | 1.95 | 0.84–3.84 |
| Testis | 3 | 1.97 | 0.41–5.77 | 4 | 2.2 | 0.6–1.67 | 0 | 0 | 0–67.97 |
| Urinary system | 151 | 1.67# | 1.41–1.95 | 90 | 1.49# | 1.2–5.64 | 6 | 1.41 | 0.52–3.07 |
| Urinary bladder | 72 | 1.42# | 1.11–1.79 | 32 | 1 | 0.68–1.83 | 2 | 0.87 | 0.11–3.14 |
| Kidney and renal pelvis | 71 | 1.89# | 1.47–2.38 | 57 | 2.13# | 1.61–2.75 | 3 | 1.65 | 0.34–4.81 |
| Kidney | 63 | 1.80# | 1.38–2.3 | 55 | 2.18# | 1.65–2.82 | 3 | 1.79 | 0.37–524 |
| Renal pelvis | 8 | 3.03# | 1.31–5.97 | 2 | 1.22 | 0.15–2.84 | 0 | 0 | 0–24.65 |
| Ureter | 6 | 3.97# | 1.46–8.65 | 1 | 1.07 | 0.03–4.42 | 1 | 11.92 | 0.3–66.4 |
| Brain and other nervous system | 16 | 1.05 | 0.6–1.71 | 20 | 1.78# | 1.08–5.95 | 0 | 0 | 0–5.04 |
| Brain | 15 | 1.05 | 0.59–1.73 | 18 | 1.70# | 1.01–2.74 | 0 | 0 | 0–5.35 |
| All lymphatic and hematopoietic diseases | 128 | 1.12 | 0.94–1.34 | 116 | 1.50# | 1.24–20.92 | 4 | 0.67 | 0.18–1.72 |
| Lymphoma | 69 | 1.12 | 0.87–1.42 | 1.16 | 52 | 0.9–1.8 | 0 | 0 | 0–1.16 |
| Hodgkin lymphoma | 4 | 0.87 | 0.24–2.22 | 5 | 1.28 | 0.42–1.59 | 0 | 0 | 0–18.28 |
| Non-Hodgkin lymphoma | 65 | 1.14 | 0.88–1.45 | 47 | 1.2 | 0.88–2.99 | 0 | 0 | 0–1.24 |
| Myeloma | 23 | 1.28 | 0.81–1.91 | 14 | 1.2 | 0.66–1.6 | 1 | 0.99 | 0.03–5.54 |
| Leukemia | 36 | 1.05 | 0.74–1.46 | 50 | 2.20# | 1.63–2.01 | 3 | 1.7 | 0.35–4.96 |
| Lymphocytic leukemia | 18 | 1.08 | 0.64–1.7 | 20 | 1.82# | 1.11–2.9 | 1 | 1.19 | 0.03–6.61 |
| Acute lymphocytic leukemia | 8 | 5.03# | 2.17–9.91 | 4 | 3.12 | 0.85–2.81 | 1 | 13.78 | 0.35–76.76 |
| Chronic lymphocytic leukemia | 10 | 0.71 | 0.34–1.31 | 16 | 1.78# | 1.02–8 | 0 | 0 | 0–5.09 |
| Nonlymphocytic leukemia | 18 | 1.03 | 0.61–1.62 | 30 | 2.55# | 1.72–2.9 | 2 | 2.16 | 0.26–7.82 |
| Acute nonlymphocytic leukemia (ANLL) | 14 | 1.19 | 0.65–2 | 19 | 2.40# | 1.45–3.64 | 1 | 1.61 | 0.04–8.99 |
| Myeloid and monocytic leukemia | 17 | 1.07 | 0.62–1.71 | 28 | 2.59# | 1.72–3.75 | 2 | 2.43 | 0.29–8.77 |
| Acute myeloid leukemia | 13 | 1.25 | 0.67–2.14 | 18 | 2.54# | 1.51–3.74 | 1 | 1.83 | 0.05–10.22 |
| Chronic myeloid leukemia | 3 | 0.67 | 0.14–1.96 | 9 | 2.92# | 1.34–12.93 | 1 | 4.41 | 0.11–24.58 |
Cancers without statistically significant elevated risk are excluded, except for ones related to other statistically significant cancers; #: p value < 0.05; 95% CI: 95% confidence interval.